J, M., C, T., E, S., L, L., SB, J., DK, K., . . . PL, C. (2025). Clinical Pharmacokinetic Assessment of Lazertinib in Healthy Adult Participants: Effects of GSTM1 Genotype. Clinical drug investigation, 45(12), 935. https://doi.org/10.1007/s40261-025-01494-z
Chicago Style (17th ed.) CitationJ, Mehta, et al. "Clinical Pharmacokinetic Assessment of Lazertinib in Healthy Adult Participants: Effects of GSTM1 Genotype." Clinical Drug Investigation 45, no. 12 (2025): 935. https://doi.org/10.1007/s40261-025-01494-z.
MLA (9th ed.) CitationJ, Mehta, et al. "Clinical Pharmacokinetic Assessment of Lazertinib in Healthy Adult Participants: Effects of GSTM1 Genotype." Clinical Drug Investigation, vol. 45, no. 12, 2025, p. 935, https://doi.org/10.1007/s40261-025-01494-z.
Warning: These citations may not always be 100% accurate.
